AR073696A1 - Composiciones transdermicas de donepezilo de liberacion prolongada y metodos para utilizar las mismas.kits - Google Patents
Composiciones transdermicas de donepezilo de liberacion prolongada y metodos para utilizar las mismas.kitsInfo
- Publication number
- AR073696A1 AR073696A1 ARP090103720A ARP090103720A AR073696A1 AR 073696 A1 AR073696 A1 AR 073696A1 AR P090103720 A ARP090103720 A AR P090103720A AR P090103720 A ARP090103720 A AR P090103720A AR 073696 A1 AR073696 A1 AR 073696A1
- Authority
- AR
- Argentina
- Prior art keywords
- donepezil
- active agent
- transdermal composition
- composition
- long
- Prior art date
Links
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical group O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 title abstract 43
- 239000000203 mixture Substances 0.000 title abstract 15
- 230000002035 prolonged effect Effects 0.000 title abstract 2
- 239000013543 active substance Substances 0.000 abstract 21
- 229960003530 donepezil Drugs 0.000 abstract 21
- 229940124532 absorption promoter Drugs 0.000 abstract 5
- 239000004820 Pressure-sensitive adhesive Substances 0.000 abstract 3
- 208000024827 Alzheimer disease Diseases 0.000 abstract 2
- SFNALCNOMXIBKG-UHFFFAOYSA-N ethylene glycol monododecyl ether Chemical group CCCCCCCCCCCCOCCO SFNALCNOMXIBKG-UHFFFAOYSA-N 0.000 abstract 2
- 238000013265 extended release Methods 0.000 abstract 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 1
- 229920002884 Laureth 4 Polymers 0.000 abstract 1
- 125000003158 alcohol group Chemical group 0.000 abstract 1
- 239000011248 coating agent Substances 0.000 abstract 1
- 238000000576 coating method Methods 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940100556 laureth-23 Drugs 0.000 abstract 1
- 229940061515 laureth-4 Drugs 0.000 abstract 1
- 229920000058 polyacrylate Polymers 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Reivindicacion 1: Una composicion transdérmica que comprende el agente activo donepezilo de liberacion prolongada, donde dicha composicion comprende: una capa de agente activo donepezilo, en la cual dicha capa de agente activo donepezilo está formulada para proveer la liberacion durante varios días de una cantidad terapéuticamente eficaz de un agente activo donepezilo a un sujeto cuando dicha composicion se aplica por vía topica a dicho sujeto. Reivindicacion 2: La composicion transdérmica que comprende el agente activo donepezilo de liberacion prolongada de acuerdo con la reivindicacion 1, en la cual dicha capa de agente activo donepezilo comprende: (a) dicho agente activo donepezilo; (b) un promotor de absorcion percutánea; y (c) un adhesivo sensible a la presion. Reivindicacion 5: La composicion transdérmica que comprende el agente activo donepezilo de liberacion prolongada de acuerdo con la reivindicacion 1, en la cual dicha capa de agente activo donepezilo comprende un agente activo donepezilo en una cantidad cuyo rango es desde 10% hasta 25% (p/p). Reivindicacion 8: La composicion transdérmica que comprende el agente activo donepezilo de liberacion prolongada de acuerdo con la reivindicacion 2, en la cual dicho promotor de absorcion percutánea es un polioxiéter de alcohol. Reivindicacion 9: La composicion transdérmica que comprende el agente activo donepezilo de liberacion prolongada de acuerdo con la reivindicacion 8, en la cual dicho polioxiéter de alcohol está descripto por la formula: CmH2m+1(OCH2CH2)nOH en la cual: m es un entero que varía desde 8 hasta 18; y n es un entero que varia desde 2 hasta 23. Reivindicacion 10: La composicion transdérmica que comprende el agente activo donepezilo de liberacion prolongada de acuerdo con la reivindicacion 9, en la cual dicho promotor de absorcion percutánea es laureth-4. Reivindicacion 11: La composicion transdérmica que comprende el agente activo donepezilo de liberacion prolongada de acuerdo con la reivindicacion 9, en la cual dicho promotor de absorcion percutánea es laureth-23. Reivindicacion 12: La composicion transdérmica que comprende el agente activo donepezilo de liberacion prolongada de acuerdo con la reivindicacion 2, en la cual dicho adhesivo sensible a la presion comprende un polímero acrílico. Reivindicacion 20: Una composicion transdérmica que comprende el agente activo donepezilo de liberacion prolongada, donde dicha composicion consiste básicamente de: (a) un apoyo; (b) una capa de agente activo donepezilo que consiste básicamente de: (i) un agente activo donepezilo; (ii) un promotor de absorcion percutánea; y (iii) un adhesivo sensible a la presion; y (c) in revestimiento de liberacion; en la cual dicha capa de agente activo donepezilo está formulada para proveer la liberacion durante varios días de una cantidad terapéuticamente eficaz de un agente activo donepezilo a un sujeto cuando dicha composicion se aplica por vía topica a dicho sujeto. Reivindicacion 25: El uso de una composicion transdérmica que contiene el agente activo donepezilo de liberacion prolongada, de acuerdo con cualquiera de las reivindicaciones 1 a 24, para la preparacion de un medicamento para el tratamiento de la enfermedad de Alzheimer y/o demencia.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10141208P | 2008-09-30 | 2008-09-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR073696A1 true AR073696A1 (es) | 2010-11-24 |
Family
ID=42057739
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090103720A AR073696A1 (es) | 2008-09-30 | 2009-09-28 | Composiciones transdermicas de donepezilo de liberacion prolongada y metodos para utilizar las mismas.kits |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20100080842A1 (es) |
| EP (1) | EP2328582A4 (es) |
| JP (1) | JP2012504163A (es) |
| CN (1) | CN102164601A (es) |
| AR (1) | AR073696A1 (es) |
| AU (1) | AU2009300184A1 (es) |
| BR (1) | BRPI0917862A2 (es) |
| CA (1) | CA2733265A1 (es) |
| IL (1) | IL210970A0 (es) |
| MX (1) | MX2011002260A (es) |
| TW (1) | TW201029653A (es) |
| WO (1) | WO2010039381A1 (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ605352A (en) * | 2010-06-30 | 2013-10-25 | Nal Pharmaceuticals Ltd | Process for producing glycosaminoglycans |
| CN103124556B (zh) * | 2010-09-30 | 2015-10-14 | 积水医疗株式会社 | 贴剂 |
| TWI433904B (zh) * | 2011-01-12 | 2014-04-11 | Taiwan Biotech Co Ltd | 多奈哌齊經皮貼片 |
| WO2013078608A1 (en) | 2011-11-29 | 2013-06-06 | Ziqiang Gu | Donepezil pamoate and methods of making and using the same |
| KR101485822B1 (ko) | 2014-01-22 | 2015-01-23 | 주식회사 대웅제약 | 도네페질 또는 그의 염을 함유하는 경피흡수제제 |
| WO2015127280A1 (en) | 2014-02-20 | 2015-08-27 | Nal Pharmaceuticals, Ltd. | Transdermal drug delivery system containing donepezil |
| RU2713207C2 (ru) * | 2014-12-18 | 2020-02-04 | Айкьюре Фармасьютикал Инк. | Трансдермальная композиция, содержащая донепезил в качестве активного ингредиента |
| KR102033686B1 (ko) | 2017-05-19 | 2019-10-18 | 보령제약 주식회사 | 도네페질을 함유하는 마이크로니들 경피 패치 |
| WO2019118782A1 (en) * | 2017-12-13 | 2019-06-20 | Corium, Inc. | Method for depot creation during transdermal drug delivery |
| KR102024996B1 (ko) | 2017-12-27 | 2019-09-25 | 동아에스티 주식회사 | 도네페질을 함유하는 치매 치료용 경피흡수제제 |
| KR102372630B1 (ko) | 2019-05-15 | 2022-03-14 | 주식회사 대웅제약 | 고함량의 도네페질 또는 그의 염을 포함하는 경피흡수제제 |
| CN112823793A (zh) * | 2019-11-20 | 2021-05-21 | 成都康弘药业集团股份有限公司 | 一种含有多奈哌齐的透皮贴剂及其制备方法 |
| WO2024127805A1 (ja) * | 2022-12-16 | 2024-06-20 | 帝國製薬株式会社 | ドネペジル含有経皮吸収製剤 |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4880633A (en) * | 1986-03-12 | 1989-11-14 | Merck & Co., Inc. | Transdermal drug delivery system |
| DE3775830D1 (de) * | 1986-06-13 | 1992-02-20 | Alza Corp | Aktivierung eines transdermalen drogenabgabesystems durch feuchtigkeit. |
| US5006342A (en) * | 1986-12-22 | 1991-04-09 | Cygnus Corporation | Resilient transdermal drug delivery device |
| US5186939A (en) * | 1987-04-23 | 1993-02-16 | Cygnus Therapeutic Systems | Laminated composite for transdermal administration of fentanyl |
| FI95572C (fi) * | 1987-06-22 | 1996-02-26 | Eisai Co Ltd | Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi |
| US4849224A (en) * | 1987-11-12 | 1989-07-18 | Theratech Inc. | Device for administering an active agent to the skin or mucosa |
| US5681579A (en) * | 1993-03-22 | 1997-10-28 | E.R. Squibb & Sons, Inc. | Polymeric support wound dressing |
| US5613958A (en) * | 1993-05-12 | 1997-03-25 | Pp Holdings Inc. | Transdermal delivery systems for the modulated administration of drugs |
| US5503844A (en) * | 1993-05-18 | 1996-04-02 | Mli Acquisition Corp. Ii | Foam laminate transdermal patch |
| DE4341444C2 (de) * | 1993-12-04 | 1996-03-14 | Lohmann Therapie Syst Lts | Wirkstoffhaltiges Pflaster und Verfahren zu seiner Herstellung |
| US5536263A (en) * | 1994-03-30 | 1996-07-16 | Lectec Corporation | Non-occulusive adhesive patch for applying medication to the skin |
| US5635203A (en) * | 1994-09-29 | 1997-06-03 | Alza Corporation | Transdermal device having decreased delamination |
| US5759560A (en) * | 1995-07-27 | 1998-06-02 | Bio Med Sciences, Inc. | Silicone thermoplastic sheeting for scar treatment and useful article thereof; process of manufacture and use |
| US5906830A (en) * | 1995-09-08 | 1999-05-25 | Cygnus, Inc. | Supersaturated transdermal drug delivery systems, and methods for manufacturing the same |
| TW513409B (en) * | 1996-06-07 | 2002-12-11 | Eisai Co Ltd | Polymorphs of donepezil hydrochloride |
| US6007837A (en) * | 1996-07-03 | 1999-12-28 | Alza Corporation | Drug delivery devices and process of manufacture |
| US5716621A (en) * | 1996-07-03 | 1998-02-10 | Pharmadyn, Inc. | Nonocclusive drug delivery device and process for its manufacture |
| US6512010B1 (en) * | 1996-07-15 | 2003-01-28 | Alza Corporation | Formulations for the administration of fluoxetine |
| ATE229817T1 (de) * | 1996-10-24 | 2003-01-15 | Alza Corp | Penetrationsfördernde substanzen für die transdermale verabreichung von wirkstoffen, vorrichtungen und verfahren zur herstellung |
| US7150881B2 (en) * | 1997-06-26 | 2006-12-19 | Mylan Technologies, Inc. | Adhesive mixture for transdermal delivery of highly plasticizing drugs |
| US6197331B1 (en) * | 1997-07-24 | 2001-03-06 | Perio Products Ltd. | Pharmaceutical oral patch for controlled release of pharmaceutical agents in the oral cavity |
| US6193993B1 (en) * | 1998-03-03 | 2001-02-27 | Eisai Co., Ltd. | Suppository containing an antidementia medicament |
| DE19830649C2 (de) * | 1998-07-09 | 2003-04-10 | Lohmann Therapie Syst Lts | Topisches Pflaster mit nichtsteroidalen Antirheumatika mit Säuregruppe |
| US6611706B2 (en) * | 1998-11-09 | 2003-08-26 | Transpharma Ltd. | Monopolar and bipolar current application for transdermal drug delivery and analyte extraction |
| US6148232A (en) * | 1998-11-09 | 2000-11-14 | Elecsys Ltd. | Transdermal drug delivery and analyte extraction |
| US6597946B2 (en) * | 1998-11-09 | 2003-07-22 | Transpharma Ltd. | Electronic card for transdermal drug delivery and analyte extraction |
| WO2000033812A2 (en) * | 1998-12-07 | 2000-06-15 | Elan Corporation, Plc | Transdermal patch for delivering volatile liquid drugs |
| US7273618B2 (en) * | 1998-12-09 | 2007-09-25 | Chiron Corporation | Method for administering agents to the central nervous system |
| US7374779B2 (en) * | 1999-02-26 | 2008-05-20 | Lipocine, Inc. | Pharmaceutical formulations and systems for improved absorption and multistage release of active agents |
| US7063859B1 (en) * | 1999-04-28 | 2006-06-20 | Noven Pharmaceuticals, Inc. | Barrier film lined backing layer composition and method for topical administration of active agents |
| US6395300B1 (en) * | 1999-05-27 | 2002-05-28 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
| US6673363B2 (en) * | 1999-12-16 | 2004-01-06 | Dermatrends, Inc. | Transdermal and topical administration of local anesthetic agents using basic enhancers |
| US6719997B2 (en) * | 2000-06-30 | 2004-04-13 | Dermatrends, Inc. | Transdermal administration of pharmacologically active amines using hydroxide-releasing agents as permeation enhancers |
| ATE345803T1 (de) * | 2000-03-03 | 2006-12-15 | Eisai Co Ltd | Neue methoden unter verwendung von cholinesteraseinhibitoren |
| DE10060852A1 (de) * | 2000-12-06 | 2002-06-20 | Hexal Ag | Absorptionsmittel und Kanalbildner enthaltende wirkstoffundurchlässige Deckschicht oder abziehbare Schutzschicht eines transdermalen therapeutischen Systems |
| US6589514B2 (en) * | 2001-04-17 | 2003-07-08 | Morinda, Inc. | Cosmetic intensive repair serum with morinda citrifolia |
| US6833478B2 (en) * | 2001-07-13 | 2004-12-21 | Sri International | N,N-dinitramide salts as solubilizing agents for biologically active agents |
| US6893655B2 (en) * | 2001-10-09 | 2005-05-17 | 3M Innovative Properties Co. | Transdermal delivery devices |
| US20040258741A1 (en) * | 2001-10-17 | 2004-12-23 | Takaaki Terahara | Percutaneous absorption preparations |
| WO2003032914A2 (en) * | 2001-10-17 | 2003-04-24 | Eisai Co., Ltd. | Methods for treating substance abuse with cholinesterase inhibitors |
| US6787682B2 (en) * | 2001-11-05 | 2004-09-07 | Hollister Incorporated | Absorbent foam wound dressing |
| EP1374812A1 (en) * | 2002-06-28 | 2004-01-02 | Biopol Co., Ltd. | Multilayered microporous foam dressing and method for manufacturing the same |
| IL150509A (en) * | 2002-07-01 | 2007-07-04 | Joseph Kaspi | Pharmaceutical preparations containing donafazil hydrochloride |
| CN1214785C (zh) * | 2002-08-27 | 2005-08-17 | 孙丽琴 | 一种用于保护眼睛的透皮控穴位贴片及其制备方法 |
| JP4792193B2 (ja) * | 2002-08-28 | 2011-10-12 | 久光製薬株式会社 | 貼付剤 |
| US7186842B2 (en) * | 2003-02-12 | 2007-03-06 | Usv, Ltd. | Polymorph of (1-benzyl-4-[(5,6-dimethoxy-1-indanone)-2-y1] methyl piperidine hydrochloride (Donepezil hydrochloride) and a process for producing thereof |
| US7439365B2 (en) * | 2003-11-17 | 2008-10-21 | Usv, Ltd. | Pharmaceutical salt of (1-benzyl-4-[(5,6-dimethoxy-1-indanone)-2-yl] methyl piperidine (Donepezil) |
| RU2356580C2 (ru) * | 2003-10-28 | 2009-05-27 | Новен Фармасьютикалз, Инк | Композиции и способы, обеспечивающие контролируемую потерю лекарственных средств и доставку в системах трансдермальной доставки лекарственных средств |
| WO2006082728A1 (ja) * | 2005-02-04 | 2006-08-10 | Hisamitsu Pharmaceutical Co., Inc. | 経皮吸収貼付剤 |
| CN101460156B (zh) * | 2006-05-08 | 2011-06-08 | 帝国制药株式会社 | 抗痴呆药的经皮吸收制剂 |
| JP5097359B2 (ja) * | 2006-05-09 | 2012-12-12 | 久光製薬株式会社 | ドネペジル経皮吸収型製剤 |
| US9248104B2 (en) * | 2006-08-17 | 2016-02-02 | Core Tech Solutions, Inc. | Transdermal methods and systems for treating Alzheimer's disease |
| BRPI0719307A2 (pt) * | 2006-12-01 | 2014-02-04 | Nitto Denko Corp | Método para a supressão da descoloração ao longo do tempo da preparação adesiva contendo donepezil. |
| US20090297591A1 (en) * | 2008-05-30 | 2009-12-03 | Orient Pharma Co., Ltd. | Compositions And Methods For The Transdermal Delivery Of Pharmaceutical Compounds |
| WO2013078608A1 (en) * | 2011-11-29 | 2013-06-06 | Ziqiang Gu | Donepezil pamoate and methods of making and using the same |
-
2009
- 2009-08-31 JP JP2011530087A patent/JP2012504163A/ja active Pending
- 2009-08-31 EP EP09818191A patent/EP2328582A4/en not_active Withdrawn
- 2009-08-31 BR BRPI0917862A patent/BRPI0917862A2/pt not_active Application Discontinuation
- 2009-08-31 CN CN200980138160XA patent/CN102164601A/zh active Pending
- 2009-08-31 CA CA2733265A patent/CA2733265A1/en not_active Abandoned
- 2009-08-31 MX MX2011002260A patent/MX2011002260A/es not_active Application Discontinuation
- 2009-08-31 US US12/551,231 patent/US20100080842A1/en not_active Abandoned
- 2009-08-31 WO PCT/US2009/055542 patent/WO2010039381A1/en active Application Filing
- 2009-08-31 AU AU2009300184A patent/AU2009300184A1/en not_active Abandoned
- 2009-09-28 AR ARP090103720A patent/AR073696A1/es not_active Application Discontinuation
- 2009-09-29 TW TW098132814A patent/TW201029653A/zh unknown
-
2011
- 2011-01-31 IL IL210970A patent/IL210970A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2009300184A1 (en) | 2010-04-08 |
| US20100080842A1 (en) | 2010-04-01 |
| IL210970A0 (en) | 2011-04-28 |
| EP2328582A1 (en) | 2011-06-08 |
| MX2011002260A (es) | 2011-04-07 |
| BRPI0917862A2 (pt) | 2015-11-24 |
| JP2012504163A (ja) | 2012-02-16 |
| WO2010039381A1 (en) | 2010-04-08 |
| EP2328582A4 (en) | 2012-02-22 |
| TW201029653A (en) | 2010-08-16 |
| CN102164601A (zh) | 2011-08-24 |
| CA2733265A1 (en) | 2010-04-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR073696A1 (es) | Composiciones transdermicas de donepezilo de liberacion prolongada y metodos para utilizar las mismas.kits | |
| BRPI0516077A (pt) | composições antimicrobianas compreendendo um agente natural selecionado de ácido gálico, eucalipotol, naringina, um composto de ácido jasmÈnico e qualquer combinação destes | |
| CL2012001056A1 (es) | Compuestos derivados de cromenona sustituidos, inhibidores de enzimas pi 3 quinasa; composicion farmaceutica; y uso en el tratamiento o prevencion de trastornos de proliferacion celular, tales como tumores enfermedades inflamatorias y fibroticas, asma, diabetes insulinodependiente, entre otras. | |
| JP2012504163A5 (es) | ||
| PE20141649A1 (es) | Composiciones farmaceuticas que comprenden 40-o-(2-hidroxi)etil-rapamicina | |
| EA201001649A1 (ru) | Алкоксилаты спирта, включающие их агенты и применение алкоксилатов спирта в качестве вспомогательных веществ в области агрохимикатов | |
| MX353841B (es) | Composiciones antimicrobianas y metodos de uso. | |
| BR112012006756A2 (pt) | revestimentos para aplicação na superfície da pele | |
| NO20080261L (no) | Alkoholsammensetninger som kan skummes, systemer og fremgangsmater av anvendelsen | |
| EA201100762A1 (ru) | Состав, содержащий октенидин | |
| UY29825A1 (es) | Derivados sustituidos de 3h-imidazol-(4,5 b (beta))piridina-2-il benzoatos y benzamidas, composiciones farmacéuticas que los contienen y aplicaciones | |
| DK1901755T3 (da) | Nye farmaceutiske sammensætninger indeholdende hyaluronsyre eller dens derivater og collagenase til topisk behandling af sår, forbrændinger og ulcera | |
| FR2968950B1 (fr) | Composition cosmetique comprenant un compose d'acide cucurbique | |
| ECSP10010352A (es) | Gel de quitosano para aplicaciones dermatologicas, proceso de obtencion y uso del mismo | |
| BR112015003403A2 (pt) | produtos de cuidado de ferida com composições de perácido | |
| FR2973229B1 (fr) | Procede cosmetique de traitement des odeurs corporelles humaines utilisant un compose 4-(3-ethoxy-4-hydroxyphenyl)alkylcetone ou 2-ethoxy 4-hydroxyalkyl phenol | |
| AR045504A1 (es) | Composicion de ester ramificado | |
| MX335945B (es) | Composicion antifungica novedosa. | |
| MX2009003035A (es) | Composiciones formadoras de pelicula que contienen mezclas de esteres de acido benzoico. | |
| RU2011150901A (ru) | Композиции и способы лечения грибковой инфекции ногтей | |
| AR063782A1 (es) | Parche y metodo transdermico para emesis | |
| PE20230002A1 (es) | Compuesto de oxazolidinona y metodos de uso de este como agente antibacteriano | |
| GEP20125392B (en) | Tricyclic compounds and pharmaceutical use thereof | |
| BRPI0411430A (pt) | composto, uso do mesmo, composição farmacêutica, kit farmacêutico, e, método de sìntese de compostos | |
| RU2013101783A (ru) | Местные бактерицидные композиции |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |